Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slowed Carboplatin Infusion in Recurrent Ovarian Cancer
NCT02035345Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of carboplatin in ovarian cancer, sponsored by Massachusetts General Hospital. Primary endpoints: Number of Participants With Carboplatin Infusion Hypersensitivity Reactions at 2 years and Number of Patients With Carboplatin Reactions of Different Severity at 2 years. Started Jan 2014; status: terminated.
02
Drugs
carboplatin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02035345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02035345.